IND Swift Laboratories Ltd
NSE:INDSWFTLAB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
70.13
120.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
IND Swift Laboratories Ltd
NSE:INDSWFTLAB
|
8.9B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
530.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
278.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.8B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
222.3B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.6B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.1B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.2B EUR |
Loading...
|
Market Distribution
| Min | -153 833.3% |
| 30th Percentile | 2.7% |
| Median | 7.3% |
| 70th Percentile | 13.2% |
| Max | 9 977% |
Other Profitability Ratios
IND Swift Laboratories Ltd
Glance View
Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The company is headquartered in Chandigarh, Chandigarh. The company went IPO on 2002-03-15. The firm operates through the bulk drugs and pharmaceuticals segment. Its business includes Active Pharmaceutical Ingredients (APIs), Advanced Intermediates, and Contract Research and Manufacturing Services (CRAMS). The firm has a product portfolio of approximately 12 therapeutic segments. The company is manufacturing APIs of complex therapies namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Multidisciplinary skills Synthetic Medicinal Chemistry Custom Synthesis Process R&D cGMP Manufacturing Analytical Development Regulatory Support Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. The Company’s products and services include API products, custom chemicals, and impurities. The firm manufacturing facilities are at Derabassi and Jammu Kashmir.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for IND Swift Laboratories Ltd is -3.7%, which is below its 3-year median of 19.4%.
Over the last 3 years, IND Swift Laboratories Ltd’s Operating Margin has decreased from 5.7% to -3.7%. During this period, it reached a low of -7.4% on Mar 31, 2025 and a high of 92.5% on Dec 31, 2024.